Global Plasma Fractionation Market – Industry Trends and Forecast to 2031

Plasma Fractionation Market Analysis and Size

The plasma fractionation market encompasses modern and traditional techniques. Modern plasma fractionation utilizes advanced technologies such as chromatography and filtration to isolate specific plasma components with enhanced purity and yield. In contrast, traditional fractionation employs methods such as precipitation and centrifugation. Instances of modern techniques include the use of monoclonal antibodies for specific protein isolation, while traditional methods include cold ethanol precipitation for general plasma fractionation.

Data Bridge Market Research analyses that the global plasma fractionation market, which was USD 29,259.96 million in 2023, is expected to reach USD 48,425.11 million by 2031, at a CAGR of 6.5% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Plasma Fractionation Market Scope and Segmentation

Market Definition

Plasma fractionation is a process used to separate various components of blood plasma, including proteins and other biological substances, for therapeutic purposes. Through fractionation, plasma-derived products such as immunoglobulins, albumin, and clotting factors are isolated and purified for use in treating various medical conditions, including immune deficiencies and bleeding disorders.

Global Plasma Fractionation Market Dynamics

Drivers

• Growing Geriatric Population Requiring Plasma Products

Elderly individuals often require plasma-derived biopharmaceuticals to treat various medical conditions, including immune deficiencies and coagulation disorders, which become more prevalent with age. This demographic trend significantly amplifies the need for plasma fractionation, as the elderly population continues to grow globally, emphasizing the critical role of plasma products in geriatric healthcare.

• Government Initiatives to Support Plasma Fractionation

Many governments implement policies and provide funding to encourage plasma donation, streamline plasma collection processes, and ensure the availability of plasma-derived products. These initiatives aim to enhance public health by addressing the increasing demand for plasma products and improving access to essential therapies. Consequently, government support acts as a key driver in sustaining growth and innovation within the plasma fractionation market.

Opportunities

• Advancements in Purification Techniques for Plasma Fractionation

Innovative methods such as chromatography and filtration enhance the efficiency and yield of plasma-derived products while ensuring high purity and safety standards. These advancements enable manufacturers to produce a wider range of high-quality plasma products, meeting diverse clinical needs. Moreover, they present opportunities for companies to differentiate themselves in the market by offering superior products and expanding their customer base.

• Collaborations with Healthcare Providers for Plasma Supply

Partnering with hospitals and clinics for plasma collection enhances access to raw materials, streamlines procurement processes, and fosters a reliable supply chain. Additionally, these collaborations present opportunities for market players to establish long-term relationships, expand their network, and tap into new sources of plasma, thereby strengthening their competitive position in the market.

Restraints/Challenges

• Competition from Alternative Therapies Impede Market

Biosimilars offer similar therapeutic effects at potentially lower costs, enticing both patients and healthcare providers. This heightened competition can lead to pricing pressures and reduced market share for plasma-derived therapies. Consequently, companies may face decreased revenues and profitability, hindering investments in research and development. Thus, competition from alternative therapies presents a notable challenge to market growth.

• Limited Availability of Plasma Donors for Collection

With fewer donors, there is a constrained supply of raw material for plasma-derived therapies, leading to production bottlenecks and potential shortages. This can disrupt manufacturing schedules, impacting product availability and revenue streams for companies. Moreover, increased competition for scarce donors may escalate collection costs, further squeezing profit margins and hindering market expansion.

This global plasma fractionation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global plasma fractionation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In October 2022, Grifols launched a new albumin purification and filling plant in Dublin, Ireland, as part of its global manufacturing and supply hub. This expansion enhances the company's capacity to produce albumin, a key component in plasma fractionation, contributing to meeting the growing demand in the plasma fractionation market
• In September 2022, CSL Behring K.K. obtained approval from Japan's Ministry of Health, Labour and Welfare for Berinert S.C. Injection 2000. This lyophilized human C1-esterase inhibitor concentrate offers subcutaneous injection for preventing acute hereditary angioedema (HAE) attacks, displaying advancements in plasma derivatives for therapeutic applications in the plasma fractionation market
• In May 2022, Terumo Blood and Cell Technologies inaugurated a $250 million production facility in Douglas County, Colorado. This 170,000-square-foot site aims to bolster healthcare contributions by manufacturing single-use collection sets for the FDA-approved Rika Plasma Donation System, catering to the increasing demand for source plasma collections in the plasma fractionation market
• In April 2020, Grifols introduced a 3-ml vial for HyperRAB, a rabies immune globulin, into the plasma fractionation market. This expansion aimed to enhance treatment options for rabies cases globally. The plasma fractionation market involves isolating and purifying plasma components for therapeutic use in various medical conditions, meeting critical healthcare demands

Global Plasma Fractionation Market Scope

The global plasma fractionation market is segmented on the basis of product type, application, processing technology, mode, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Immunoglobulins
• Intravenous
• Subcutaneous
• Coagulation Factor Concentrates
• Factor IX
• Factor VIII
• Prothrombin Complex Concentrates
• Fibrinogen Concentrates
• Others
• Albumin
• Protease Inhibitors
• Other Products

Application

• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Hemato- Oncology
• Rheumatology
• Others

Processing Technology

• Ion- Exchange Chromatography
• Affinity Chromatography
• Cryopreservation
• Ultrafiltration
• Microfiltration

 Mode

• Modern Plasma Fractionation
• Traditional Plasma Fractionation

 End User

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutions
• Others

Distribution Channel

• Direct Tenders
• Third Party Distribution
• Others

Global Plasma Fractionation Market Regional Analysis/Insights

The global plasma fractionation market is analysed and market size insights and trends are provided by product type, application, processing technology, mode, end user and distribution channel as referenced above.

The countries covered in the global plasma fractionation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the global plasma fractionation market, driven by rising usage of plasma-derived products and innovative developments. Within North America, the U.S. dominates with the highest CAGR, attributed to heightened awareness of plasma's benefits. This trend underscores the region's pivotal role in advancing plasma fractionation technologies and therapies.

In the Asia-Pacific region, China emerges as a dominant force in the global plasma fractionation market, fueled by surging demand and heightened health awareness. The nation's robust healthcare infrastructure and growing emphasis on human health underscore its pivotal role in driving advancements and meeting the rising demand for plasma fractionation products.

In Europe, Germany leads the market due to its large geriatric population and prevalence of immune deficiency diseases. These factors drive significant demand for plasma fractionation products, positioning Germany as a dominant player in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global plasma fractionation market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global plasma fractionation market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global plasma fractionation market. The data is available for historic period 2016-2021.

Competitive Landscape and Global Plasma Fractionation Market Share Analysis

The global plasma fractionation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global plasma fractionation market.

Some of the major players operating in the global plasma fractionation market are:

• Grifols, S.A. (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• Octapharma AG (Switzerland)
• CSL Plasma (Australia)
• Japan Blood Products Organization (Japan)
• China Biologic Products Holdings, Inc. (China)
• LFB SA (France)
• Green Cross Corp. (South Korea)
• Shanghai RAAS (China)
• Baxter (U.S.)
• Bio Products Laboratory Ltd. (U.K.)
• Novasep Holding SAS (France)
• Pall Corporation (U.S.)
• KabaFusion (U.S.)
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
• Bharat Serums and Vaccines Limited (India)
• SK Plasma (South Korea)
• Kedrion S.p.A (Italy)
• Sanquin (Netherlands)
• Biotest AG (Germany)
• Merck KGaA (Germany)
• ADMA Biologics, Inc. (U.S.)
• Boccard (France)
• Intas Pharmaceuticals Ltd. (India)
• CENTURION Ilaç Sanayi ve Ticaret A.S. (Turkey)

SKU-10878